Abstract | BACKGROUND: METHODS: The study was performed as a crossover design, and ten unresectable or relapsed gastric cancer patients were randomly divided into two groups. Group A (n = 5) was started on Rikkunshito (2.5 g three times daily, orally) from the first course of chemotherapy and followed by a second course without Rikkunshito. A treatment with reversed order was performed for Group B (n = 5). All patients received combined chemotherapy with S-1 plus cisplatin. The primary endpoint was the amount of oral intake, and the categories of scales of anorexia, nausea, and vomiting; secondary endpoints included the plasma concentration of acylated ghrelin. RESULTS: CONCLUSION:
|
Authors | Tetsuro Ohno, Mitsuhiro Yanai, Hiroyuki Ando, Yoshitaka Toyomasu, Atsushi Ogawa, Hiroki Morita, Kyoichi Ogata, Erito Mochiki, Takayuki Asao, Hiroyuki Kuwano |
Journal | Clinical and experimental gastroenterology
(Clin Exp Gastroenterol)
Vol. 4
Pg. 291-6
( 2011)
ISSN: 1178-7023 [Electronic] New Zealand |
PMID | 22235173
(Publication Type: Journal Article)
|